MXPA02005005A - Nueva composicion y uso. - Google Patents

Nueva composicion y uso.

Info

Publication number: MXPA02005005A
Authority: MX; Mexico
Prior art keywords: thiazolidinedione; metformin; composition based; novel composition; pharmaceutically acceptable
Prior art date: 1999-11-16

Application number

MXPA02005005A

Other languages

English (en)

Inventor

Karen Lewis

Original Assignee

Smithkline Beecham Plc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-11-16

Filing date

2000-11-16

Publication date

2003-10-14

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27447849&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MXPA02005005(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1999-11-16 Priority claimed from GBGB9927119.9A external-priority patent/GB9927119D0/en

1999-11-16 Priority claimed from GBGB9927120.7A external-priority patent/GB9927120D0/en

2000-05-31 Priority claimed from GB0013236A external-priority patent/GB0013236D0/en

2000-05-31 Priority claimed from GB0013240A external-priority patent/GB0013240D0/en

2000-11-16 Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc

2003-10-14 Publication of MXPA02005005A publication Critical patent/MXPA02005005A/es

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Hematology (AREA)
Obesity (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)

MXPA02005005A 1999-11-16 2000-11-16 Nueva composicion y uso. MXPA02005005A (es)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
GBGB9927119.9A GB9927119D0 (en)	1999-11-16	1999-11-16	Novel composition and use
GBGB9927120.7A GB9927120D0 (en)	1999-11-16	1999-11-16	Novel composition and use
GB0013236A GB0013236D0 (en)	2000-05-31	2000-05-31	Novel composition and use
GB0013240A GB0013240D0 (en)	2000-05-31	2000-05-31	Novel composition and use
PCT/GB2000/004368 WO2001035941A2 (en)	1999-11-16	2000-11-16	Novel composition based on a thiazolidinedione and metformin and use

Publications (1)

Publication Number	Publication Date
MXPA02005005A true MXPA02005005A (es)	2003-10-14

Family

ID=27447849

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MXPA02005005A MXPA02005005A (es)	1999-11-16	2000-11-16	Nueva composicion y uso.

Country Status (40)

Country	Link
US (1)	US8236345B2 (es)
EP (3)	EP1520581A1 (es)
JP (2)	JP4865975B2 (es)
KR (1)	KR100760063B1 (es)
CN (1)	CN1222290C (es)
AP (1)	AP1389A (es)
AR (2)	AR030920A1 (es)
AT (1)	ATE292466T1 (es)
AU (3)	AU775654B2 (es)
BG (1)	BG65616B1 (es)
BR (1)	BR0015605A (es)
CA (1)	CA2388846A1 (es)
CO (1)	CO5300392A1 (es)
CZ (1)	CZ302500B6 (es)
DE (1)	DE60019329T2 (es)
DK (1)	DK1231918T3 (es)
DZ (1)	DZ3251A1 (es)
EA (1)	EA004878B1 (es)
ES (1)	ES2240199T3 (es)
HK (1)	HK1049788B (es)
HR (1)	HRP20020416B1 (es)
HU (1)	HU229960B1 (es)
IL (3)	IL149618A0 (es)
MA (1)	MA25567A1 (es)
ME (1)	ME00318B (es)
MX (1)	MXPA02005005A (es)
MY (1)	MY125516A (es)
NO (1)	NO329926B1 (es)
NZ (1)	NZ518946A (es)
OA (1)	OA12513A (es)
PE (1)	PE20011011A1 (es)
PL (1)	PL200943B1 (es)
PT (1)	PT1231918E (es)
RS (1)	RS51343B (es)
SI (1)	SI1231918T1 (es)
SK (1)	SK286985B6 (es)
TW (1)	TWI240626B (es)
UA (1)	UA73150C2 (es)
UY (1)	UY26439A1 (es)
WO (1)	WO2001035941A2 (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE60129425T2 (de) *	2000-05-01	2008-04-17	Aeropharm Technology LLC, Dover	Kernformulierung
CA2453782A1 (en) *	2001-07-10	2003-01-23	Kos Life Sciences, Inc.	Core formulation comprising troglitazone and a biguanide
GB0203296D0 (en) *	2002-02-12	2002-03-27	Glaxo Group Ltd	Novel composition
EP1515701B1 (en) *	2002-06-17	2014-09-17	Inventia Healthcare Private Limited	Process for the manufacture of multilayer tablet compositions comprising thiazolidinedione and biguanide
CA2492722A1 (en) *	2002-07-11	2004-01-22	Takeda Pharmaceutical Company Limited	Production method of coated preparations
US8637512B2 (en) *	2002-07-29	2014-01-28	Glaxo Group Limited	Formulations and method of treatment
US7959946B2 (en)	2002-09-20	2011-06-14	Watson Pharmaceuticals, Inc.	Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
KR101363679B1 (ko) *	2002-09-20	2014-02-14	안드렉스 랩스 엘엘씨	약제학적 정제
US9060941B2 (en)	2002-09-20	2015-06-23	Actavis, Inc.	Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7785627B2 (en)	2002-09-20	2010-08-31	Watson Pharmaceuticals, Inc.	Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US8084058B2 (en)	2002-09-20	2011-12-27	Watson Pharmaceuticals, Inc.	Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
UA80991C2 (en) *	2002-10-07	2007-11-26		Solid preparation containing an insulin resistance improving drug and an active ingredient useful as a remedy for diabetes
WO2004067001A1 (ja)	2003-01-29	2004-08-12	Takeda Pharmaceutical Company Limited	被覆製剤の製造法
FR2858556B1 (fr) *	2003-08-06	2006-03-10	Galenix Innovations	Composition pharmaceutique solide dispersible et/ou orodispersible non pelliculee contenant au moins le principe actif metformine, et procede de preparation
US8263121B2 (en)	2004-04-14	2012-09-11	Takeda Pharmaceutical Company Limited	Solid pharmaceutical preparation
WO2006011397A1 (ja) *	2004-07-27	2006-02-02	Kowa Company., Ltd.	糖尿病の予防または治療のための薬剤
PL1878426T3 (pl)	2005-04-26	2010-11-30	Sumitomo Dainippon Pharma Co Ltd	Preparat w formie granulatu zawierający związek biguanidu
JP5179363B2 (ja) *	2005-12-22	2013-04-10	武田薬品工業株式会社	固形製剤
FR2896159B1 (fr)	2006-01-13	2008-09-12	Merck Sante Soc Par Actions Si	Combinaison de derives de triazine et d'agents sensibilisateurs a l'insuline.
GB2456996B (en)	2006-12-26	2011-09-21	Fujitsu Ltd	Data compression apparatus and data decompression apparatus
EA015180B1 (ru)	2007-02-01	2011-06-30	Такеда Фармасьютикал Компани Лимитед	Твердый препарат, содержащий алоглиптин и пиоглитазон
US9095519B2 (en)	2007-02-09	2015-08-04	Alphapharm Pty Ltd	Dosage form containing two or more active pharmaceutical ingredients in different physical forms
TR200803177A2 (tr) *	2008-05-06	2009-11-23	Bi̇li̇m İlaç Sanayi̇ Ti̇caret A.Ş.	Antihiperglisemik etkili metformîn - pioglitazon formülasyonu.
KR20160127181A (ko)	2008-08-12	2016-11-02	진판델 파마슈티컬스 인코포레이티드	질환 위험 인자의 식별 방법
US8846315B2 (en)	2008-08-12	2014-09-30	Zinfandel Pharmaceuticals, Inc.	Disease risk factors and methods of use
FR2951945B1 (fr) *	2009-11-05	2013-08-09	Sanofi Aventis	Composition pharmaceutique
CA2780939C (en) *	2009-11-13	2018-06-12	Bristol-Myers Squibb Company	Bilayer tablet formulations
EP2441442A1 (en)	2010-10-08	2012-04-18	LEK Pharmaceuticals d.d.	A pharmaceutical composition comprising a thiazolidinedione
US8796338B2 (en)	2011-01-07	2014-08-05	Elcelyx Therapeutics, Inc	Biguanide compositions and methods of treating metabolic disorders
US11974971B2 (en)	2011-01-07	2024-05-07	Anji Pharmaceuticals Inc.	Compositions and methods for treating metabolic disorders
US11759441B2 (en)	2011-01-07	2023-09-19	Anji Pharmaceuticals Inc.	Biguanide compositions and methods of treating metabolic disorders
SI2661266T1 (sl)	2011-01-07	2021-01-29	Anji Pharma (Us) Llc	Terapije, na osnovi kemosenzoričnih receptorskih ligandov
US9480663B2 (en)	2011-01-07	2016-11-01	Elcelyx Therapeutics, Inc.	Biguanide compositions and methods of treating metabolic disorders
US9211263B2 (en)	2012-01-06	2015-12-15	Elcelyx Therapeutics, Inc.	Compositions and methods of treating metabolic disorders
US9572784B2 (en)	2011-01-07	2017-02-21	Elcelyx Therapeutics, Inc.	Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
UA114704C2 (uk)	2011-01-10	2017-07-25	Зінфандел Фармасьютікалз, Інк.	Способи та лікарські засоби для лікування хвороби альцгеймера
BR112014016810A8 (pt)	2012-01-06	2017-07-04	Elcelyx Therapeutics Inc	composições e métodos para tratamento de distúrbios metabólicos
MX2014008190A (es)	2012-01-06	2015-02-04	Elcelyx Therapeutics Inc	Composiciones de biguanida y métodos para tratar transtornos metabólicos.
CN108451923B (zh) *	2018-05-31	2025-05-06	常州兰陵制药有限公司	盐酸二甲双胍速释胶囊及其制备方法
JP2023528565A (ja)	2020-04-01	2023-07-05	ハンジョウジョンメイフアドンファーマシューティカルシーオー．，エルティーディー．	Ｇｌｐ－１受容体アゴニストの結晶形ａおよびその調製法
WO2021196951A1 (zh)	2020-04-01	2021-10-07	杭州中美华东制药有限公司	Glp-1受体激动剂游离碱的药学上可接受的酸式盐及其制备方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS4613596Y1 (es) *	1969-06-02	1971-05-14
DE2347531A1 (de) *	1973-09-21	1975-04-30	Hoechst Ag	Arzneizubereitungen zur oralen diabetes-behandlung
EP0306228B1 (en) *	1987-09-04	1999-11-17	Beecham Group Plc	Substituted thiazolidinedione derivatives
US4999226A (en) *	1988-06-01	1991-03-12	Merrell Dow Pharmaceuticals Inc.	Pharmaceutical compositions for piperidinoalkanol-ibuprofen combination
JPH0553521A (ja)	1991-08-28	1993-03-05	Mitsubishi Electric Corp	オートトラツキング型ｃｒｔデイスプレイモニタ
GB9218830D0 (en) *	1992-09-05	1992-10-21	Smithkline Beecham Plc	Novel compounds
IT1255522B (it)	1992-09-24	1995-11-09	Ubaldo Conte	Compressa per impiego terapeutico atta a cedere una o piu' sostanze attive con differenti velocita'
US6183778B1 (en) *	1993-09-21	2001-02-06	Jagotec Ag	Pharmaceutical tablet capable of liberating one or more drugs at different release rates
TWI238064B (en) *	1995-06-20	2005-08-21	Takeda Chemical Industries Ltd	A pharmaceutical composition for prophylaxis and treatment of diabetes
DE19539361A1 (de) *	1995-10-23	1997-04-24	Basf Ag	Verfahren zur Herstellung von mehrschichtigen, festen Arzneiformen zur oralen oder rektalen Verabreichung
GB9612496D0 (en)	1996-06-14	1996-08-14	De La Rue Thomas & Co Ltd	Security device
PE71699A1 (es)	1997-02-07	1999-08-03	Sepracor Inc	Composicion farmaceutica de descarboetoxiloratadina sin lactosa, no higroscopica y anhidra
CZ298469B6 (cs) *	1997-06-18	2007-10-10	Smithkline Beecham Plc	Farmaceutický prostredek obsahující 5-[4-/2-(N-methyl-N-(2-pyridyl)amino)ethoxy/benzyl]thiazolidin-2,4-dion a metformin, a lécivo pro lécení diabetesmellitus
US20020004515A1 (en) *	1997-06-18	2002-01-10	Smith Stephen Alistair	Treatment of diabetes with thiazolidinedione and metformin
GB9715295D0 (en) *	1997-07-18	1997-09-24	Smithkline Beecham Plc	Novel method of treatment
EA003101B1 (ru) *	1998-03-19	2002-12-26	Бристол-Майерз Сквибб Компани	Двухфазная система доставки с регулируемым высвобождением для фармацевтических средств с высокой растворимостью и способ лечения диабета с помощью этой системы
US6099859A (en) *	1998-03-20	2000-08-08	Andrx Pharmaceuticals, Inc.	Controlled release oral tablet having a unitary core
US6117451A (en) *	1998-08-25	2000-09-12	Pharmalogix, Inc.	Direct compression metformin hydrochloride tablets
SK287038B6 (sk)	1998-11-12	2009-10-07	Smithkline Beecham Plc	Farmaceutický prostriedok na postupné uvoľňovanie 5-[4-[2-(N- metyl-N-(2-pyridyl)amino)etoxy]benzyl]tiazolidín-2,4-diónu a metformínu a spôsob jeho výroby
US20040102486A1 (en) *	1998-11-12	2004-05-27	Smithkline Beecham Corporation	Novel method of treatment
DZ2937A1 (fr)	1998-11-12	2004-03-15	Smithkline Beecham Plc	Compositions nouvelles de sensibilidants à l'insuline.
GB9824893D0 (en)	1998-11-12	1999-01-06	Smithkline Beckman Corp	Novel method of treatment
US20040081697A1 (en) *	1998-11-12	2004-04-29	Smithkline Beecham P.L.C.	Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
EP1231917A2 (en)	1999-11-16	2002-08-21	Smithkline Beecham Plc	Pharmaceutical composition comprising a thiazolidinedione-metformin hydrochloride
US6403121B1 (en) *	2000-05-01	2002-06-11	Aeropharm Technology Incorporated	Core formulation
US6461639B2 (en) *	2000-05-01	2002-10-08	Aeropharm Technology, Inc.	Core formulation
US6524621B2 (en) *	2000-05-01	2003-02-25	Aeropharm Technology Inc.	Core formulation
US6780432B1 (en) *	2000-05-01	2004-08-24	Aeropharm Technology, Inc.	Core formulation
US6296874B1 (en) *	2000-05-01	2001-10-02	Aeropharm Technology Incorporated	Core formulation comprising troglitazone and abiguanide
US6451342B2 (en) *	2000-05-01	2002-09-17	Aeropharm Technology Incorporated	Core formulation comprised of troglitazone and a biguanide
GB0318824D0 (en) *	2003-08-11	2003-09-10	Glaxo Group Ltd	Novel composition

2000
- 2000-11-15 AR ARP000106019A patent/AR030920A1/es active IP Right Grant
- 2000-11-15 MY MYPI20005360A patent/MY125516A/en unknown
- 2000-11-16 HK HK03100745.5A patent/HK1049788B/en not_active IP Right Cessation
- 2000-11-16 HR HR20020416A patent/HRP20020416B1/xx not_active IP Right Cessation
- 2000-11-16 ME MEP-2008-340A patent/ME00318B/me unknown
- 2000-11-16 SK SK679-2002A patent/SK286985B6/sk not_active IP Right Cessation
- 2000-11-16 PL PL355331A patent/PL200943B1/pl unknown
- 2000-11-16 EA EA200200571A patent/EA004878B1/ru not_active IP Right Cessation
- 2000-11-16 EP EP04078538A patent/EP1520581A1/en not_active Withdrawn
- 2000-11-16 EP EP07120386A patent/EP1913945A3/en not_active Withdrawn
- 2000-11-16 DE DE60019329T patent/DE60019329T2/de not_active Expired - Lifetime
- 2000-11-16 NZ NZ518946A patent/NZ518946A/en not_active IP Right Cessation
- 2000-11-16 BR BR0015605-1A patent/BR0015605A/pt not_active Application Discontinuation
- 2000-11-16 RS YUP-388/02A patent/RS51343B/sr unknown
- 2000-11-16 HU HU0204122A patent/HU229960B1/hu unknown
- 2000-11-16 MX MXPA02005005A patent/MXPA02005005A/es active IP Right Grant
- 2000-11-16 UA UA2002064826A patent/UA73150C2/uk unknown
- 2000-11-16 CN CNB008178224A patent/CN1222290C/zh not_active Expired - Lifetime
- 2000-11-16 UY UY26439A patent/UY26439A1/es not_active IP Right Cessation
- 2000-11-16 PE PE2000001226A patent/PE20011011A1/es not_active Application Discontinuation
- 2000-11-16 IL IL14961800A patent/IL149618A0/xx unknown
- 2000-11-16 ES ES00976156T patent/ES2240199T3/es not_active Expired - Lifetime
- 2000-11-16 SI SI200030697T patent/SI1231918T1/xx unknown
- 2000-11-16 AT AT00976156T patent/ATE292466T1/de active
- 2000-11-16 AU AU14040/01A patent/AU775654B2/en not_active Expired
- 2000-11-16 KR KR1020027006271A patent/KR100760063B1/ko not_active Expired - Lifetime
- 2000-11-16 WO PCT/GB2000/004368 patent/WO2001035941A2/en not_active Ceased
- 2000-11-16 AP APAP/P/2002/002505A patent/AP1389A/en active
- 2000-11-16 JP JP2001537934A patent/JP4865975B2/ja not_active Expired - Lifetime
- 2000-11-16 EP EP00976156A patent/EP1231918B1/en not_active Expired - Lifetime
- 2000-11-16 DZ DZ003251A patent/DZ3251A1/fr active
- 2000-11-16 DK DK00976156T patent/DK1231918T3/da active
- 2000-11-16 PT PT00976156T patent/PT1231918E/pt unknown
- 2000-11-16 CZ CZ20021679A patent/CZ302500B6/cs not_active IP Right Cessation
- 2000-11-16 OA OA1200200145A patent/OA12513A/en unknown
- 2000-11-16 CA CA002388846A patent/CA2388846A1/en not_active Abandoned
- 2000-11-20 CO CO00088045A patent/CO5300392A1/es not_active Application Discontinuation
- 2000-12-04 TW TW089125730A patent/TWI240626B/zh not_active IP Right Cessation
2002
- 2002-05-13 IL IL149618A patent/IL149618A/en unknown
- 2002-05-15 MA MA26640A patent/MA25567A1/fr unknown
- 2002-05-15 NO NO20022334A patent/NO329926B1/no not_active IP Right Cessation
- 2002-05-29 BG BG106747A patent/BG65616B1/bg unknown
2004
- 2004-11-04 AU AU2004226955A patent/AU2004226955B2/en not_active Expired
2006
- 2006-12-05 AR ARP060105370A patent/AR057970A2/es active IP Right Grant
2007
- 2007-07-18 US US11/779,546 patent/US8236345B2/en not_active Expired - Fee Related
2008
- 2008-03-17 IL IL190220A patent/IL190220A0/en unknown
- 2008-08-18 AU AU2008207375A patent/AU2008207375A1/en not_active Abandoned
2011
- 2011-08-11 JP JP2011175883A patent/JP5282130B2/ja not_active Expired - Lifetime

Also Published As

Publication number	Publication date
EA004878B1 (ru)	2004-08-26
HK1049788A1 (en)	2003-05-30
HRP20020416A2 (en)	2004-08-31
AR057970A2 (es)	2007-12-26
HUP0204122A2 (hu)	2003-03-28
WO2001035941A2 (en)	2001-05-25
AP2002002505A0 (en)	2002-06-30
BG106747A (en)	2003-01-31
AU1404001A (en)	2001-05-30
CZ302500B6 (cs)	2011-06-22
UA73150C2 (uk)	2005-06-15
ES2240199T3 (es)	2005-10-16
MY125516A (en)	2006-08-30
SI1231918T1 (en)	2005-08-31
AU2004226955B2 (en)	2008-08-28
IL190220A0 (en)	2008-11-03
UY26439A1 (es)	2001-07-31
CA2388846A1 (en)	2001-05-25
KR20030019300A (ko)	2003-03-06
EA200200571A1 (ru)	2002-12-26
PE20011011A1 (es)	2001-10-28
AU775654B2 (en)	2004-08-12
MEP34008A (en)	2011-02-10
JP2011252007A (ja)	2011-12-15
NO20022334L (no)	2002-07-09
CN1414852A (zh)	2003-04-30
AU2004226955A1 (en)	2004-12-02
PL200943B1 (pl)	2009-02-27
US8236345B2 (en)	2012-08-07
HRP20020416B1 (hr)	2011-04-30
TWI240626B (en)	2005-10-01
JP5282130B2 (ja)	2013-09-04
EP1231918B1 (en)	2005-04-06
HU229960B1 (hu)	2015-03-30
ME00318B (me)	2011-05-10
NO329926B1 (no)	2011-01-24
IL149618A (en)	2008-07-08
JP4865975B2 (ja)	2012-02-01
EP1520581A1 (en)	2005-04-06
RS51343B (sr)	2011-02-28
NO20022334D0 (no)	2002-05-15
NZ518946A (en)	2003-10-31
MA25567A1 (fr)	2002-10-01
AR030920A1 (es)	2003-09-03
EP1231918A2 (en)	2002-08-21
IL149618A0 (en)	2002-12-01
WO2001035941A8 (en)	2002-08-29
BR0015605A (pt)	2002-07-09
SK286985B6 (sk)	2009-08-06
DZ3251A1 (fr)	2001-05-25
JP2003514012A (ja)	2003-04-15
CN1222290C (zh)	2005-10-12
HUP0204122A3 (en)	2006-01-30
YU38802A (sh)	2005-03-15
PT1231918E (pt)	2005-08-31
DE60019329D1 (de)	2005-05-12
PL355331A1 (en)	2004-04-19
US20070275054A1 (en)	2007-11-29
ATE292466T1 (de)	2005-04-15
OA12513A (en)	2006-05-29
SK6792002A3 (en)	2002-09-10
BG65616B1 (bg)	2009-03-31
DK1231918T3 (da)	2005-08-01
HK1049788B (en)	2005-11-04
EP1913945A2 (en)	2008-04-23
DE60019329T2 (de)	2006-03-09
CO5300392A1 (es)	2003-07-31
WO2001035941A3 (en)	2002-05-23
KR100760063B1 (ko)	2007-09-18
AP1389A (en)	2005-04-14
EP1913945A3 (en)	2008-04-30
AU2008207375A1 (en)	2008-09-11

Publication	Publication Date	Title
MXPA02005005A (es)	2003-10-14	Nueva composicion y uso.
DE69931925D1 (de)	2006-07-27	2-chinolonen enthaltende arzneimittel
CA2420694A1 (en)	2002-03-07	Guanidinobenzamides as mc4-r agonists
IL172695A0 (en)	2006-04-10	Novel medicament compositions, based on anticholinergically effective compounds and beta-mimetics
GEP20074099B (en)	2007-05-10	3-β-D-RIBOFURANO-SYLTHIAZOLO[4,5-d]PYRIDIMINE NUCLEOSIDES AND USES THEREOF
NO2013019I2 (no)	2013-12-17	Aliskiren eller et farmasøytisk akseptabelt salt derav, og hydroklortiazid eller et farmasøytisk akseptabelt salt derav.
HUP0401567A3 (en)	2005-06-28	Novel 4,5-dyhydro-1h-pyrazole derivatives having cb1-antagonistic activity, their use and pharmaceutical compositions containing them
DE60230340D1 (de)	2009-01-22	N-Ä4-(4-Amino-2-ethyl-1H-imidazoÄ4,5-cÜchinolin-1-yl)butylÜmethanesulfonamide, diese enthaltende pharmazeutische Zusammensetzung und deren Verwendung
HUP0400932A3 (en)	2007-11-28	Pharmaceutical composition containing nateglinide and another antidiabetic compound, process for its preparation and for use the same
HUP0004310A3 (en)	2001-11-28	Cyclic amino acids, and derivatives thereof and pharmaceutical compositions comprising the said compounds as active agents
ZA200203368B (en)	2003-09-02	Pharmaceutical composition comprising a combination of metformin and glibenclamide.
HUP0200714A3 (en)	2003-01-28	Pharmaceutical compounds, pharmaceutical compositions containing them and their use
EP1595543A3 (en)	2006-08-02	Antineoplastic pharmaceutical compositions comprising taurolidine or taurultam and 5-fluorouracil
IL141997A0 (en)	2002-03-10	Novel n-(iminomethyl) amine derivatives, their preparation, their use as medicines and compositions containing them
WO2001035940A3 (en)	2002-03-21	Pharmaceutical composition comprising a thiazolidinedione-metformin hydrochloride
GEP20074123B (en)	2007-06-11	Amino acids with affinity for the alpha−2−delta−protein
HRP20040171A2 (en)	2004-10-31	Combined preparations, containing 1,4-benzothiepine-1,1-dioxide derivatives and other active substances, and the use thereof
DE69815094D1 (de)	2003-07-03	2-(iminoethyl)-aminophenyl - derivate, deren herstellung, deren verwendung als medikamente und diese enthaltende pharmazeutische zubereitungen
HUP0200996A3 (en)	2003-01-28	Amine derivatives, pharmaceutical compositions containing them and their use
WO2002067865A3 (en)	2003-03-20	N-(aryl)-2-arylethenesulfonamides and therapeutic uses thereof
CA2350659A1 (en)	2000-05-25	Pharmaceutical composition for modified release insulin sensitiser
AU1650501A (en)	2001-06-12	1,3,4-oxadiazoline derivatives and drugs containing these derivatives as the active ingredient
ZA200203311B (en)	2003-12-31	Pharmaceutical carrier formulation.
ES2191908T3 (es)	2003-09-16	4-aminopirrol(3,2-d)pirimidinas como antagonistas del receptor del neuropeptido.
EP1234834A4 (en)	2003-01-29	1,3,4-OXADIAZOLINE-2-ONE DERIVATIVES AND MEDICINAL PRODUCTS CONTAINING SUCH DERIVATIVES USEFUL AS ACTIVE INGREDIENT

Legal Events

Date	Code	Title	Description
2006-05-30	FG	Grant or registration